Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 19/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 17/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.61 |
| ▸ | PIK3CB | P42338 | 14/20 | 0.61 |
| ▸ | PIK3C3 | Q8NEB9 | 4/20 | 0.56 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.56 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.56 |
| ▸ | PI4KA | P42356 | 1/20 | 0.56 |
| ▸ | PRKDC | P78527 | 1/20 | 0.56 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.56 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL571448 | 0.82 | PIK3CG (0.71) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL1889405 | 0.81 | PIK3CA (0.50) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL10670937 | 0.81 | PIK3CG (0.72) | PIK3CGPIK3CDPIK3CAPIK3CBPI4KB | |
| SCHEMBL925027 | 0.81 | PIK3CG (0.64) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL4516245 | 0.80 | MEN1 (0.70) | PIK3CG | |
| SCHEMBL942547 | 0.80 | PIK3CA (0.61) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL48907 | 0.80 | PIK3CG (0.62) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL925932 | 0.80 | PIK3CA (0.57) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 | |
| SCHEMBL15803671 | 0.79 | PIK3CA (0.64) | PIK3CGPIK3CDPIK3CAPIK3CBPI4KB | |
| SCHEMBL48462 | 0.79 | PIK3CG (0.69) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2157091-B1 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2015-06-10 | — | — | EP | disclosed |
| US-20130172349-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-8404684-B2 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2013-03-26 | — | — | US | disclosed |
| US-20110105535-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG | 2011-05-05 | — | — | US | disclosed |
| US-7868188-B2 | 5-heteroaryl thiazoles and their use as PI3K inhibitors | ASTRAZENECA AB (SE) | 2011-01-11 | — | — | US | disclosed |
| CN-1816549-B | Phosphatidylinositol 3-kinase inhibitors | NOVARTIS AG | 2010-09-29 | — | — | CN | disclosed |
| EP-1841763-B1 | 5-HETEROARYL THIAZOLES AND THEIR USE AS PI3K INHIBITORS | ASTRAZENECA AB (SE) | 2010-06-30 | — | — | EP | disclosed |
| EP-2157091-A1 | Inhibitors of phosphatidylinositol 3-kinase | Novartis AG (CH) | 2010-02-24 | — | — | EP | disclosed |
| CN-101648949-A | inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG CH | 2010-02-17 | — | — | CN | disclosed |
| EP-1622897-B1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2009-10-14 | — | — | EP | disclosed |
| US-20080132502-A1 | 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
| US-20070032487-A1 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2007-02-08 | — | — | US | disclosed |
| CN-1816549-A | Phosphatidylinositol 3-kinase inhibitors | NOVARTIS AG (CH) | 2006-08-09 | — | — | CN | disclosed |
| EP-1622897-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Novartis AG (CH) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004096797-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032487-A1 | Inhibitors of phosphatidylinositol 3-kinase | PIK3CA, PIP4K2C, PIP4K2B | PIK3CG 10/4885PIK3CD 4/4885PIK3CA 1/4885 |
| US-20110105535-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIP4K2C | PIK3CG 8/4885PIK3CD 2/4885PIK3CA 1/4885 |
| US-20080132502-A1 | 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors | MTOR, PIK3R5, PIK3CA | PIK3CG 16/4885PIK3CD 6/4885PIK3CA 3/4885 |
| US-20130172349-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIP4K2C | PIK3CG 8/4885PIK3CD 2/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.